worldwid
preval
herp
simplex
viru
hsv
shortag
effici
vaccin
novel
therapeut
strategi
hsv
wide
global
concern
abund
virion
major
stimulu
virusneutr
antibodi
make
gd
predomin
candid
cure
hsv
infect
studi
gener
monoclon
antibodi
mab
term
target
glycoprotein
gd
also
crossreact
gd
high
level
neutral
activ
bind
highli
conserv
region
residu
within
profus
domain
gd
effect
block
hsv
celltocel
spread
vitro
preor
postattach
neutral
assay
syncytium
format
inhibit
assay
reveal
neutral
hsv
postbind
stage
moreov
therapeut
administr
complet
prevent
infectionrel
mortal
mice
challeng
lethal
dose
newli
identifi
epitop
neutral
antibodi
would
facilit
studi
gdbase
hsv
entri
vaccin
design
demonstr
high
potenti
adapt
protect
therapeut
drug
hsv
herp
simplex
viru
hsv
preval
worldwid
human
pathogen
infect
epitheli
cell
establish
latenc
trigemin
sacral
nerv
root
ganglia
steiner
benning
caus
mucocutan
lesion
kerat
enceph
dropul
cohen
two
serotyp
hsv
also
known
human
herpesviru
common
clinic
sign
herp
labiali
well
ocular
diseas
includ
conjunct
kerat
everett
main
caus
recurr
genit
herp
one
predomin
sexual
transmit
diseas
infect
newborn
deliveri
usual
accompani
high
mortal
rate
cleari
et
al
domeika
et
al
overal
moreov
epidemiolog
biolog
studi
reveal
dramat
increas
risk
hiv
infect
barnaba
celum
freeman
et
al
sartori
et
al
may
also
act
conjunct
human
papillomaviru
hpv
infect
increas
risk
invas
cervic
carcinoma
smith
et
al
zhao
et
al
accord
world
health
organ
statist
million
peopl
age
year
live
infect
worldwid
looker
et
al
newli
infect
popul
estim
million
per
year
looker
et
al
therefor
develop
vaccin
novel
therapeut
strategi
hsv
becom
urgent
initi
entri
virion
cell
subsequ
later
spread
hsv
requir
interact
four
viral
glycoprotein
gb
gd
gh
gl
least
one
cell
receptor
either
herpesviru
entri
mediat
hvem
among
viral
glycoprotein
gd
act
receptorbind
glycoprotein
gh
gl
gb
requir
membran
fusion
execut
gd
ectodomain
organ
two
structur
function
differenti
region
n
terminu
residu
carri
receptor
bind
site
c
terminu
function
profus
domain
residu
requir
trigger
viruscel
fusion
natur
c
terminu
gd
ectodomain
bind
ntermin
region
mask
receptorbind
site
result
close
conform
cocchi
et
al
fusco
et
al
bind
cell
surfac
receptor
either
hvem
gd
undergo
conform
chang
adopt
open
conform
key
step
activ
core
fusion
machineri
ghgl
gb
gd
abundantli
express
glycoprotein
virion
induc
humor
cellular
immun
major
stimulu
virusneutr
antibodi
togeth
gb
bender
et
al
eisenberg
et
al
fotouhi
et
al
nicola
et
al
whitbeck
et
al
therefor
gd
predomin
candid
hsv
vaccin
novel
therapeut
strategi
awasthi
friedman
shin
iwasaki
monoclon
antibodi
mab
repres
use
tool
studi
structur
function
target
protein
virushost
interact
well
develop
promis
therapeut
agent
antigd
mab
arrang
group
recogn
distinct
discontinu
nativ
continu
denatur
epitop
mab
virusneutr
activ
recogn
discontinu
epitop
residu
extracellular
domain
major
continu
antigen
determin
gd
isola
et
al
mab
recogn
epitop
locat
continu
determin
region
low
virusneutr
abil
except
mab
neutral
viral
infect
block
gdreceptor
interact
cairn
et
al
current
investig
found
mab
recogn
new
continu
epitop
residu
within
profus
domain
hsv
possess
high
level
virusneutr
activ
show
high
degre
neutral
activ
complet
abrog
viral
celltocel
spread
inhibit
syncytium
format
vitro
addit
also
exhibit
highli
therapeut
effect
infect
mous
model
impli
high
potenti
adapt
protect
therapeut
intervent
cell
line
use
studi
african
green
monkey
kidney
vero
cell
line
atcc
babi
hamster
kidney
bhk
cell
line
atcc
cell
cultur
dulbecco
modifi
eagl
medium
dmem
thermo
fisher
scientif
fetal
bovin
serum
fb
thermo
fisher
scientif
f
strain
strain
kindli
provid
microorgan
virus
cultur
collect
center
wuhan
institut
virolog
ca
serial
number
virus
propag
vero
cell
cell
lysat
stock
prepar
previous
describ
morrison
knipe
viru
titer
determin
vero
cell
navarro
et
al
femal
balbc
mice
sixweek
age
purchas
hubei
provinci
center
diseas
control
prevent
wuhan
china
maintain
specif
pathogenfre
condit
structur
fulllength
gd
protein
shown
top
truncat
gd
protein
use
sequenti
map
experi
shown
number
indic
amino
acid
posit
domain
profus
defin
accord
fusco
et
al
b
recognit
region
map
mab
truncat
gd
protein
express
vector
present
antigen
use
primari
antibodi
respect
western
blot
analysi
central
anim
laboratori
wuhan
institut
virolog
chines
academi
scienc
wiv
ca
licens
number
anim
experi
approv
institut
anim
ethic
committe
wiv
ca
approv
procedur
carri
pentobarbit
sodium
sigma
anesthesia
effort
made
minim
suffer
number
anim
use
studi
mab
gd
protein
prepar
describ
previous
evan
et
al
brief
nucleotid
sequenc
encod
ectodomain
residu
plu
natur
signal
sequenc
gd
protein
clone
vector
novagen
express
escherichia
coli
protein
purifi
denatur
condit
presenc
urea
use
ninitrilotriacet
acid
nta
column
dialyz
pirestani
et
al
quantiti
purifi
protein
confirm
sodium
dodecyl
sulfat
polyacrylamid
gel
electrophoresi
sdspage
balbc
mice
n
immun
purifi
complet
freund
adjuv
sigma
week
immun
repeat
conjug
incomplet
freund
adjuv
sigma
fusion
myeloma
cell
carri
use
standard
methodolog
de
stgroth
scheidegg
hybridoma
cultur
supernat
screen
enzymelink
immunosorb
assay
elisa
western
blot
analysi
total
strain
posit
hybridoma
cell
obtain
mab
purifi
protein
sigma
accord
manufactur
instruct
epitop
map
ectodomain
gd
protein
dissect
seven
truncat
fragment
two
adjac
fragment
share
overlap
amino
acid
fig
amino
acid
gd
protein
truncat
eight
fragment
fig
nucleotid
encod
fragment
pcramplifi
use
primer
pair
list
tabl
clone
neb
express
e
coli
character
recogn
special
vero
cell
infect
multipl
infect
moi
pfu
per
cell
harvest
h
post
infect
pi
rins
pb
protein
sampl
separ
sdspage
transfer
onto
polyvinyliden
fluorid
pvdf
membran
merck
millipor
massachusett
usa
transblot
apparatu
biorad
western
blot
analys
perform
primari
antibodi
gener
abovement
screen
posit
hybridoma
cell
gd
protein
preimmun
mous
serum
sigma
antibodi
use
control
wash
blot
incub
horseradish
peroxidaseconjug
goat
antimous
antibodi
immunoreact
signal
visual
supersign
west
pico
chemiluminesc
substrat
fermenta
microchemi
bioimag
system
dnr
usa
vero
monolay
infect
moi
pfu
per
cell
h
pi
cell
fix
paraformaldehyd
min
permeabil
triton
wash
three
time
phosphatebuff
salin
pb
character
recogn
special
immunostain
cell
respect
h
preimmun
mous
serum
mous
immunoglobulin
g
beyotim
use
control
antibodi
dilut
block
solut
bsa
pb
wash
three
time
pb
cell
incub
secondari
antibodi
fluorescein
isothiocyan
fitc
conjug
goat
antimous
igg
abcam
hangzhou
china
cell
observ
fluoresc
microscopi
hsv
neutral
assay
base
previous
describ
protocol
bag
et
al
brief
vero
cell
seed
well
plate
costar
incub
overnight
achiev
confluent
monolay
serial
dilut
dmem
supplement
fb
combin
pfuwel
respect
final
concentr
rang
final
concentr
rang
preimmun
mous
serum
use
neg
control
virusantibodi
mixtur
incub
h
gentl
rock
h
incub
mixtur
inocul
vero
cell
monolay
plate
h
h
adsorpt
cell
cover
overlay
media
methylcellulos
form
plaqu
plaqu
develop
h
incub
fix
visual
stain
crystal
violet
plaqu
count
percentag
inhibit
determin
rel
neg
control
effect
concentr
mab
inhibit
number
viral
plaqu
interpol
doserespons
curv
viru
neutral
assay
repeat
least
twice
report
number
plaqu
rel
control
sem
preor
postattach
neutral
assay
perform
describ
modif
krawczyk
et
al
briefli
virusantibodi
mixtur
incub
h
inocul
vero
cell
preattach
prechil
min
vero
cell
infect
pfuwel
h
allow
viru
adsorpt
serial
dilut
antibodi
ad
postattach
inocul
vero
cell
incub
h
neutral
efficaci
determin
h
describ
standard
neutral
assay
celltocel
spread
assay
base
previous
describ
protocol
krawczyk
et
al
bhk
cell
grown
glass
coverslip
incub
overnight
achiev
confluent
monolay
cell
infect
moi
pfu
per
cell
h
adsorpt
viru
inoculum
remov
cell
wash
twice
pb
incub
dmem
contain
fb
presenc
antibodi
mous
igg
medium
alon
use
control
visual
viral
spread
immunofluoresc
h
pi
cell
fix
paraformaldehyd
permeabil
triton
wash
three
time
pb
cell
incub
mous
polyclon
antibodi
gd
primari
antibodi
fitcconjug
goat
antimous
igg
secondari
antibodi
immunofluoresc
imag
observ
fluoresc
microscopi
quantifi
celltocel
spread
number
infect
cell
gfp
fluoresc
per
total
cell
calcul
nine
randomli
chosen
area
repres
cell
group
percentag
infect
determin
rel
control
experi
repeat
twice
syncytium
format
inhibit
assay
perform
describ
modif
navarro
et
al
brief
monolay
vero
cell
grown
plate
infect
moi
pfu
per
cell
h
adsorpt
viru
inoculum
remov
cell
wash
pb
twice
incub
dmem
contain
fb
presenc
antibodi
mous
igg
medium
alon
control
h
pi
cell
fix
stain
hematoxylineosin
stain
inhibit
syncytium
format
examin
light
microscopi
quantifi
inhibit
syntytium
format
number
nuclei
syncytia
count
randomli
chosen
area
percentag
inhibit
determin
rel
antibodi
treatment
group
syncytia
contain
nuclei
analyz
three
independ
experi
calcul
mous
intravagin
challeng
establish
previous
describ
cenadiez
et
al
sixweeksold
femal
balbc
mice
render
suscept
infect
subcutan
inject
mg
medoxyprogesteron
acet
sigma
day
prior
challeng
parr
et
al
mice
randomli
assign
five
group
mice
anesthet
pentobarbit
sodium
intravagin
challeng
infect
mice
passiv
immun
intraven
inject
mgkg
h
intravagin
challeng
pb
group
set
control
mice
group
examin
daili
symptom
genit
diseas
bodi
weight
day
well
mortal
day
diseas
score
grade
appar
infect
score
genit
erythema
score
moder
genit
infect
score
purul
genit
ulcer
hair
loss
gener
poor
condit
score
sever
ulcer
genit
surround
tissu
hind
limb
paralysi
score
mice
develop
loss
bodi
weight
debilit
symptom
diseas
paralysi
sacrif
consid
die
follow
day
surviv
analys
surviv
mice
sacrif
indic
time
infect
data
present
mean
standard
error
mean
sem
sequenc
align
perform
dnaman
statist
analysi
perform
use
graphpad
prism
signific
differ
analyz
logrank
mantelcox
test
gehanbreslowwilcoxon
test
pvalu
calcul
statist
signific
report
highli
signific
use
p
p
p
origin
magnif
c
viru
neutral
assay
pfuwel
incub
indic
serial
dilut
antibodi
preimmun
serum
h
pi
cell
stain
number
plaqu
count
percentag
inhibit
determin
rel
neg
control
repres
data
mean
sem
three
independ
experi
shown
develop
function
monoclon
antibodi
gd
immun
balbc
mice
purifi
extracellular
domain
gd
protein
primari
screen
hybridoma
elisa
western
blot
analysi
immunofluoresc
assay
ifa
total
strain
posit
hybridoma
cell
obtain
tabl
epitop
map
mab
determin
use
express
truncat
gd
protein
includ
overlap
amino
acid
pair
adjac
fragment
fig
western
blot
analysi
data
shown
among
mab
anoth
mab
recogn
truncat
locat
cterminu
residu
gd
ectodomain
fig
contrast
fig
remain
mab
recogn
ntermin
fragment
suggest
recogn
overlap
region
residu
two
fragment
therefor
two
kind
mab
repres
recogn
differ
epitop
gd
chosen
character
character
specif
recognit
abil
first
test
abil
recogn
denatur
nativ
form
gd
gd
western
blot
assay
ifa
western
blot
analysi
reveal
react
expect
gd
band
sampl
infect
vero
cell
recogn
gd
infect
vero
cell
sampl
infect
sampl
fig
ifa
result
demonstr
detect
nativ
form
gd
cell
infect
either
detect
nativ
gd
cell
infect
fig
result
suggest
could
recogn
denatur
nativ
form
gd
could
recogn
denatur
nativ
form
gd
confirm
whether
could
neutral
hsv
infect
viru
neutral
assay
perform
either
pfuwel
preincub
serial
dilut
mab
infect
vero
monolay
cell
preimmun
mous
serum
use
neg
control
neutral
assay
demonstr
neutral
dosedepend
manner
infect
infect
inhibit
antibodi
concentr
contrast
demonstr
neutral
activ
low
neutral
activ
infect
group
viru
infect
inhibit
concentr
ml
fig
result
suggest
neutral
mab
infect
shown
high
level
neutral
activ
recogn
linear
epitop
locat
cterminu
gd
ectodomain
ident
accur
epitop
recogn
construct
seri
truncat
ctermin
region
residu
gd
protein
fig
western
blot
analysi
could
recogn
indic
last
ctermin
amino
acid
critic
bind
fig
similarli
first
ntermin
amino
acid
critic
bind
basi
pnwhip
consid
precis
epitop
bind
sequenc
align
show
residu
highli
conserv
among
fig
result
explain
recogn
gd
protein
direct
transmiss
adjac
cell
celltocel
spread
effici
rout
hsv
bypass
host
immun
system
neutral
mab
prevent
celltocel
spread
herpesvirus
co
et
al
hook
et
al
therefor
block
celltocel
spread
consid
import
aspect
evalu
vivo
protect
effici
neutral
antibodi
herein
analyz
abil
inhibit
celltocel
spread
vitro
confluent
bhk
cell
monolay
initi
incub
either
moi
pfu
per
cell
prevent
viral
spread
viral
particl
move
across
cell
cultur
supernat
cellfre
spread
bhk
cell
monolay
treat
excess
treatment
mous
igg
cultur
medium
alon
perform
control
h
pi
transmiss
viru
detect
immunostain
mous
polyclon
antibodi
gd
shown
fig
complet
inhibit
celltocel
spread
evidenc
observ
limit
fluoresc
caus
viru
infect
contrast
neither
mous
igg
could
suffici
inhibit
transmiss
extens
viru
spread
bhk
cell
monolay
observ
immunostain
infect
cell
quantifi
result
clearli
show
abl
inhibit
celltocel
transmiss
hsvinfect
cell
fig
character
mode
action
analyz
whether
mab
could
inhibit
receptor
bind
compar
neutral
efficaci
antibodi
ad
preattach
postattach
hsv
virion
interact
vero
cell
chosen
neg
control
preor
postattach
assay
ad
virushost
interact
preattach
infect
inhibit
concentr
fig
infect
inhibit
concentr
ad
virion
interact
vero
cell
postattach
fig
almost
equal
neutral
efficaci
observ
irrespect
fig
block
celltocel
spread
monolay
bhk
cell
infect
moi
pfu
per
cell
cell
monolay
treat
excess
antibodi
mous
igg
cultur
medium
alon
perform
control
h
pi
cell
fix
observ
fluoresc
microscopi
bar
repres
experi
repeat
least
twice
b
number
infect
cell
gfp
fluoresc
per
total
cell
calcul
randomli
chosen
area
percentag
infect
determin
rel
control
experi
repeat
twice
p
p
p
whether
antibodi
ad
virion
interact
vero
cell
contrast
neg
control
neutral
abil
either
virion
incub
cell
infect
group
show
similar
result
infect
inhibit
preattach
treatment
fig
infect
inhibit
postattach
treatment
antibodi
concentr
fig
contrast
low
infect
inhibit
neutral
abil
preattach
postattach
treatment
respect
fig
exist
data
indic
interfer
viru
bind
process
therefor
neutral
hsv
entri
postbind
stage
bind
gd
cell
surfac
receptor
undergo
conform
chang
also
key
event
trigger
later
step
lead
fusion
sinc
might
neutral
hsv
entri
postbind
stage
ask
whether
could
inhibit
virusinduc
membran
fusion
process
monolay
vero
cell
infect
moi
pfu
per
cell
h
adsorpt
viru
inoculum
remov
cell
wash
twice
pb
cell
incub
excess
mous
igg
medium
alon
control
h
syncytium
format
observ
stain
stain
shown
fig
infect
group
obviou
syncytia
multinuclear
cell
observ
infect
cell
treat
preimmun
serum
mous
igg
howev
cell
incub
syncytium
format
almost
complet
inhibit
syncytium
format
inhibit
vero
cell
differ
treatment
quantifi
fig
result
suggest
inde
inhibit
hsvinduc
membran
fusion
investig
protect
efficaci
vivo
exploit
fig
neutral
postbind
stage
comparison
neutral
efficaci
serial
dilut
antibodi
ad
c
preattach
b
postattach
hsv
virion
interact
vero
cell
use
control
neutral
efficaci
determin
h
describ
standard
neutral
assay
percent
inhibit
determin
rel
neg
control
repres
data
mean
sem
least
independ
experi
perform
shown
r
du
et
al
antivir
research
lethal
femal
balbc
mice
model
hsv
infect
assess
therapeut
effici
mice
randomli
assign
five
group
pbstreat
group
intravagin
infect
sixweeksold
femal
balbc
mice
result
rapid
progress
diseas
fig
steadi
decreas
bodi
weight
day
post
infect
fig
median
surviv
time
day
fig
experiment
group
balbc
mice
treat
intraven
mgkg
antibodi
h
intravagin
challeng
shown
fig
mice
receiv
mgkg
slightli
protect
lethal
infect
bodi
weight
group
decreas
fast
pbstreat
group
median
surviv
time
day
longer
control
mice
treat
pb
howev
mice
treat
mgkg
higher
concentr
complet
protect
lethal
infect
fig
symptom
infect
fig
loss
bodi
weight
observ
among
group
fig
glycoprotein
gd
abund
glycoprotein
virion
major
stimulu
virusneutr
antibodi
hsv
vaccin
design
novel
therapeut
strategi
import
studi
epitop
gd
stimul
virusneutr
antibodi
accord
properti
panel
mab
gd
gd
mutant
use
defin
relationship
gd
structur
function
antigd
mab
previous
arrang
group
recogn
distinct
discontinu
nativ
continu
denatur
epitop
mab
recogn
discontinu
nativ
epitop
virusneutr
activ
exampl
recogn
residu
recogn
residu
recogn
residu
recogn
residu
report
previous
neutral
mab
recogn
discontinu
conform
epitop
lazear
et
al
muggeridg
et
al
nicola
et
al
fig
inhibit
syncytium
format
vero
cell
infect
moi
pfu
per
cell
incub
dmem
contain
fb
presenc
antibodi
mous
igg
medium
alon
use
control
h
cell
fix
stain
stain
inhibit
syncytium
format
observ
light
microscopi
bar
repres
experi
repeat
least
twice
b
syncytium
format
vero
cell
differ
treatment
shown
panel
quantifi
count
number
nuclei
syncytia
randomli
chosen
area
percentag
inhibit
determin
rel
antibodi
treatment
group
syncytia
contain
nuclei
analyz
data
repres
three
independ
experi
p
p
p
whitbeck
et
al
also
number
report
mab
recogn
continu
denatur
epitop
hsv
gd
among
mab
low
virusneutr
abil
except
mab
recogn
residu
neutral
viral
infect
block
gdreceptor
interact
cairn
et
al
studi
found
novel
mab
anoth
virusneutr
mab
whose
epitop
locat
within
continu
antigen
determin
epitop
map
assay
indic
recogn
conserv
residu
locat
ctermin
profus
domain
residu
gd
fig
sequenc
align
analysi
show
epitop
highli
conserv
among
broad
rang
hsv
strain
data
shown
may
also
explain
recognit
specif
typecommon
like
efficaci
among
diverg
isol
yet
breadth
neutral
activ
panel
isol
vitro
need
perform
addit
resist
evalu
alanin
scan
also
carri
futur
recognit
specif
typecommon
high
level
hsv
virion
neutral
activ
fig
epitop
three
report
typecommon
mab
recogn
residu
recogn
residu
recogn
residu
continu
also
locat
ctermin
profus
domain
gd
howev
neutral
activ
strain
ko
strain
isola
et
al
lazear
et
al
previous
hook
colleagu
found
human
murin
cmv
vaccinia
could
spread
presenc
neutral
antibodi
gener
rabbit
hook
et
al
co
et
al
human
two
murin
monoclon
antibodi
hsv
gb
gd
shown
neutral
vitro
howev
neither
human
murin
antigd
mab
abl
protect
viral
spread
human
murin
antigb
mab
protect
cell
viral
spread
co
et
al
research
show
abl
inhibit
celltocel
spread
vitro
fig
effici
way
hsv
bypass
host
immun
system
direct
transmiss
adjac
cell
knowledg
first
epitopemap
neutral
mab
hsv
gd
report
capabl
inhibit
celltocel
spread
antibodi
entri
glycoprotein
abil
neutral
virion
via
interf
receptor
bind
subsequ
fusion
event
exampl
antibodi
target
stalk
globular
subunit
spike
protein
sever
acut
respiratori
syndrom
sar
coronaviru
abl
abolish
bind
protein
cellular
receptor
mab
neutral
hiv
inhibit
bind
receptor
wibmer
et
al
zeng
et
al
abovement
neutral
mab
neutral
viru
block
bind
gd
receptor
hvem
addit
mani
report
mab
block
viru
entri
postreceptorbind
step
instanc
neutral
mab
specif
ctermin
domain
murin
leukemia
viru
mulv
surfac
su
envelop
protein
subunit
interfer
postattach
event
necessari
membran
fusion
burkhart
et
al
mab
f
subunit
helicoverpa
armigera
nucleopolyhedroviru
f
protein
neutral
viru
entri
inhibit
membran
fusion
zou
et
al
data
preattach
postattach
neutral
assay
indic
interfer
viru
bind
process
instead
might
neutral
hsv
entri
postbind
stage
fig
observ
hsvinduc
membran
fusion
follow
treatment
determin
could
almost
complet
inhibit
syncytium
format
fig
confirm
could
inhibit
membran
fusion
event
rather
viru
bind
process
consist
current
find
earlier
studi
cocchi
et
al
fusco
et
al
establish
profus
domain
residu
requir
viral
infect
fusion
receptor
bind
substitut
pro
residu
pfd
amino
acid
affect
step
entri
fusion
howev
detail
mechan
inhibit
hsv
fusion
process
need
studi
base
high
level
hsv
virion
neutral
activ
also
investig
whether
applic
could
confer
protect
vivo
exploit
lethal
intravagin
infect
femal
balbc
mous
model
evalu
potenc
therapeut
altern
counteract
hsv
infect
data
demonstr
mab
confer
protect
dosedepend
manner
mgkg
provid
full
protect
fig
consist
intracutan
inject
human
recombin
neutral
mab
specif
gd
typecommon
epitop
locat
residu
protect
mice
effect
administ
system
zeitlin
et
al
passiv
immun
immunocompet
anim
gd
specif
mab
typecommon
fig
protect
mice
lethal
infect
symptom
genit
diseas
group
score
daili
describ
text
day
intravagin
challeng
data
shown
mean
valu
mice
group
b
mice
weigh
daili
bodi
weight
express
percentag
valu
prior
treatment
data
repres
mean
standard
error
n
anim
per
group
pb
n
group
c
surviv
mice
group
monitor
indic
day
n
anim
per
group
pb
n
group
data
analyz
logrank
mantelcox
test
gehanbreslowwilcoxon
test
p
p
neutral
mab
discontinu
epitop
locat
residu
postexposur
appropri
time
demonstr
protect
strain
htz
mp
mutant
strain
mp
strain
g
induc
neurolog
diseas
dix
et
al
pereira
et
al
furthermor
intravagin
administ
murin
antigb
mab
post
infect
confer
full
protect
immunodefici
nonobes
diabet
nod
sever
combin
immunodefici
scid
mous
model
krawczyk
et
al
result
encourag
potenc
neutral
mab
clinic
therapi
sever
hsv
diseas
conclus
result
demonstr
first
time
mab
target
new
continu
epitop
residu
within
profus
domain
high
level
virusneutr
activ
find
enrich
hsv
glycoprotein
dspecif
neutral
antibodi
facilit
develop
vaccin
design
novel
therapeut
strategi
